Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

SBR00036

Sigma-Aldrich

Rhodamine B labeled Polymyxin B Ready Made Solution

For fluorescent microbial imaging, 1.1 mg/mL in water

Sinonimo/i:

SRB-PMB

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Codice UNSPSC:
12352211
NACRES:
NA.47

Livello qualitativo

100

Concentrazione

1.1 mg/mL in water

Tipo di lipide

saturated FAs

Temperatura di conservazione

−20°C

Descrizione generale

Rhodamine B labeled polymyxin B (SRB-PMB) is a fluorescent derivative of Polymyxin B. Rhodamine B polymyxin B is an additional fluorescent derivative of Polymyxin B, along with Dansyl labeled polymyxin B (Product # SBR00029). Both products′ mode of action is in accordance with Polymyxin B activity. Fluorescent antibiotics are obtained by synthetic conjugation of an antibiotic to a fluorophore.

Applicazioni

Fluorescent antibiotics can be used for many applications including:
  • Antimicrobial resistance research.
  • Bacterial visualization and imaging.
  • Parent antibiotic mode of action research and new antibiotic discovery.
  • Toxicity studies.
  • Research of bacterial infections and tracking its uptake in vivo.

Additional possible applications for Rhodamine B labeled Polymyxin B:
  • Evaluate LPS binding by FRET (fluorescence resonance energy transfer) studies to form a specific complex between fluorescein (FITC)-tagged LPS and Polymyxin B, indicating direct binding of the antibiotic to the LPS
  • Can be applied as a fluorescent probe to study polymyxin mode of action and its pharmacokinetics
  • to assess the mitochondrial function of polymyxin B in a kidney cell line (LLC-PK1), suggesting that it changes the mitochondrial membrane polarization.

Risultati analitici

  • Rhodamine B labeled polymyxin B Ready Made Solution is light sensitive.
  • It is recommended to avoid freeze-thaw cycles of Rhodamine B labeled polymyxin B Ready-Made Solution
  • Rhodamine B labeled polymyxin B Ready Made Solution (1.1mg/mL) can be diluted 1:100-200 in PBSX1 (Product# D8537) to achieve 0.55-1.1μg/mL final concentration for staining. The above concentration of Rhodamine B labeled polymyxin B was used for Escherichia coli staining (see image)
  • Fluorescence Microscopy application: Rhodamine B labeled polymyxin B Ready Made Solution excitation (Ex) wavelength is 550-560nm resulting in emission (Em) range of 580-610nm (λmax=590-600nm)

Codice della classe di stoccaggio

12 - Non Combustible Liquids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

P R Schindler et al.
Antimicrobial agents and chemotherapy, 8(1), 95-104 (1975-07-01)
Though the primary action of the cationic antibiotic polymyxin B is against the membrane of susceptible bacteria, severe morphological changes are detected in the cytoplasm. Using fluorescence microscopy and a mono-N-dansyl-polymyxin B derivative, we could demonstrate aggregations of the antibiotic
Kinetics and Mechanism of the Recognition of Endotoxin by Polymyxin B
Thomas C J, et al.
Journal of the American Chemical Society, 120(48), 12428-12434 (1998)
R E Hancock
Lancet (London, England), 349(9049), 418-422 (1997-02-08)
The era of the "classical antibiotic" may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest
Zakuan Z Deris et al.
Bioconjugate chemistry, 25(4), 750-760 (2014-03-19)
The dry antibiotic development pipeline coupled with the emergence of multidrug resistant Gram-negative 'superbugs' has driven the revival of the polymyxin lipopeptide antibiotics. Polymyxin resistance implies a total lack of antibiotics for the treatment of life-threatening infections. The lack of
Vincent H Tam et al.
Antimicrobial agents and chemotherapy, 49(9), 3624-3630 (2005-08-30)
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in vitro pharmacodynamics of PB against four strains of Pseudomonas aeruginosa. Clonal relatedness of the strains
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.